ReviewBritish journal of pharmacology2017
Serelaxin in clinical development: past, present and future.
Review in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration.Journal of biomedical science · 2025Article
- RNA nanotherapeutics with fibrosis overexpression and retention for MASH treatment.Nature communications · 2024Article
- Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models.Scientific reports · 2022Article
- Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.Journal of personalized medicine · 2022Review
- Single-cell RNA sequencing reveals the mesangial identity and species diversity of glomerular cell transcriptomes.Nature communications · 2021Article
- Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment.Frontiers in cardiovascular medicine · 2021Review
- Efficacy of relaxin for cisplatin-induced testicular dysfunction and epididymal spermatotoxicity.Basic and clinical andrology · 2020Article
- Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart.Journal of the American Heart Association · 2019Article
- Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Intraarticular injection of relaxin-2 alleviates shoulder arthrofibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes.Endocrine · 2018Article
- CorrectionBritish journal of pharmacology · 2017Article
- Serelaxin in clinical development: past, present and future.British journal of pharmacology · 2017Review
- Recent progress in the understanding of relaxin family peptides and their receptors.British journal of pharmacology · 2017Article
Corrections and comments
- Erratum issuedCorrection2017
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The availability of highly purified recombinant human relaxin, serelaxin, has allowed clinical trials to be conducted in several indications and the elucidation of its pharmacology in human subjects. These studies have demonstrated that serelaxin has unique haemodynamic properties that are likely to contribute to organ protection and long-term outcome benefits in acute heart failure. Clinical observations support its consideration for therapeutic use in other patient populations, including those with chronic heart failure, coronary artery disease, portal hypertension and acute renal failure. LINKED ARTICLES: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.